Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12702680 | 1.00 | ALDH1A1 (0.49) | ALDH1A1HTTLMNASMN1; SMN2MGLL | |
| SCHEMBL9871000 | 0.98 | HTT (0.49) | ALDH1A1HTTLMNASMN1; SMN2MGLL | |
| SCHEMBL11543689 | 0.84 | HTT (0.47) | ALDH1A1HTTLMNASMN1; SMN2MEN1 | |
| SCHEMBL11544900 | 0.84 | HTT (0.47) | ALDH1A1HTTLMNASMN1; SMN2MEN1 | |
| SCHEMBL11543554 | 0.82 | PAOX (0.51) | ALDH1A1HTTLMNASMN1; SMN2MGLL | |
| SCHEMBL3608245 | 0.82 | SMN1; SMN2 (0.51) | ALDH1A1HTTLMNASMN1; SMN2MEN1 | |
| SCHEMBL6681364 | 0.80 | HTT (0.51) | ALDH1A1HTTLMNASMN1; SMN2MEN1 | |
| SCHEMBL8971899 | 0.78 | L3MBTL1 (0.67) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8973343 | 0.78 | L3MBTL1 (0.67) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL474080 | 0.78 | L3MBTL1 (0.67) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215888-A1 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2009-08-27 | — | — | US | claimed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2007098591-A2 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2007-09-07 | — | — | WO | claimed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| CN-110636833-B | Topical treatment of cutaneous malignant tumors using taxane nanoparticles | DFB索里亚有限责任公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-3595633-B1 | TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES | DFB SORIA LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | DFB SORIA, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11583499-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20090215888-A1 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2009-04-23 | — | — | US | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| WO-2007098591-A2 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2007-09-07 | — | — | WO | disclosed |
| US-20070183936-A1 | Apparatus and methods for evaluating the barrier properties of a membrane | NUVO RESEARCH US, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | ALDH1A1 3787/4885HTT 3642/4885LMNA 2927/4885 |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | KRT18, TUBB3, TUBA3E | ALDH1A1 1145/4885HTT 4095/4885LMNA 1915/4885 |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | ALDH1A1 3787/4885HTT 3642/4885LMNA 2927/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | ALDH1A1 1320/4885HTT 3773/4885LMNA 3441/4885 |
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | NOTUM, TRPV1, TRPV4 | ALDH1A1 777/4885HTT 4313/4885LMNA 2766/4885 |
| US-11583499-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | ALDH1A1 4040/4885HTT 3496/4885LMNA 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.